Rheinbio (002166): Excellent performance in 24Q1, synthetic biotechnology builds long-term advantages
Rhine Biotech (002166) Company Incident Review Report: The impact of inventory removal has subsided, and the profit side is expected to rise steadily
Tianfeng Securities released a research report on April 17 stating that it gave Rhine Biotech (002166.SZ) a purchase rating. The main reasons for the rating include: 1) downstream customers are under pressure to inventory the company's performance; 2) the
RheinBio (002166): Performance accelerated improvement in 23Q4, optimistic about the continued volume of large orders for natural sweeteners
Rheinland Biotech (002166): 1H23 It's time for the industry to go to the inventory adjustment period and polish the company's long-term competitiveness
Rhine Biotech (002166) Q23 report review: Order fulfillment from major customers in the order in which orders are fulfilled, and continue to pay attention to production capacity implementation
Rheinland Biotech (002166): Revenue is in line with expectations, implant extraction business is growing steadily
Rhine Biotech (002166) 22nd Annual Report Review: Steady Expansion of Core Business Focusing on the Long-term Growth of Emerging Categories
Rhine Biotech (002166): The future can be expected to stabilize the main business and strengthen the barriers to good
RheinBio (002166): Natural sweeteners grow strongly, industrial hemp disrupts performance
Rhine Biotech (002166): Sugar reduction surges are following the trend and stepping up new horizons
Rhine Biotech (002166): Sugar reduction surges are following the trend and stepping up new horizons
Rheinland Biotech (002166): Laying out microbial synthesis methods to maintain long-term competitive advantage
Rhine Biotech (002166): Continued investment in biosynthesis sets a high barrier for the US CBD business to welcome favorable policies
Rheinland Biotech (002166): Continued high growth in results for the first three quarters of 2022, strong demand for natural sweeteners
Rhine Biotech (002166): Continued release of natural sweeteners with strong certainty of rapid growth
Rhine Biotech (002166) 2022 third quarter report review: Overall performance is in line with expectations, growth potential is still strong
Rhine Biotech (002166): Demand for implant production business increased in 22Q3, performance continued to grow rapidly
RWE (002166) 22 years the first three quarters of the results forecast comments: high demand, continued performance, high growth, medium-and long-term growth potential is sufficient
Comments on equity incentive event of RWE (002166): equity incentive shows confidence in development and is optimistic about follow-up high-speed growth.
No Data